IPP Bureau

Ami Organics bets on strategic acquisitions as its IPO opens on Sept 1
Ami Organics bets on strategic acquisitions as its IPO opens on Sept 1

By IPP Bureau - September 01, 2021

The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio

WHO releases compendium of innovative health technologies
WHO releases compendium of innovative health technologies

By IPP Bureau - September 01, 2021

The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap

Zymo Research receives CE Mark for new Covid-19 SafeCollect kits
Zymo Research receives CE Mark for new Covid-19 SafeCollect kits

By IPP Bureau - September 01, 2021

Self-collection devices designed for ease of use and safety

Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab
Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab

By IPP Bureau - September 01, 2021

JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis

SK Bioscience and GSK start Phase 3 trial of an adjuvanted COVID-19 vaccine candidate
SK Bioscience and GSK start Phase 3 trial of an adjuvanted COVID-19 vaccine candidate

By IPP Bureau - September 01, 2021

Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine

Metropolis Healthcare opens new testing centre in Thalassery, Kerala
Metropolis Healthcare opens new testing centre in Thalassery, Kerala

By IPP Bureau - September 01, 2021

The lab will offer about 4,000 different tests ranging from basic to high-end molecular diagnostic tests

Two major hospitals in Gujarat announce tie-up
Two major hospitals in Gujarat announce tie-up

By IPP Bureau - September 01, 2021

Aashka Hospitals has entered into a non-binding agreement for its proposed tie-up with Vaidehi—Backbone hospital, Rajkot

Sher-I-Kashmir Institute of Medical Sciences and Medtronic partner to open Surgical Skills Lab
Sher-I-Kashmir Institute of Medical Sciences and Medtronic partner to open Surgical Skills Lab

By IPP Bureau - September 01, 2021

The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise

US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723
US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723

By IPP Bureau - August 31, 2021

The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers

US FDA grants Lantern Pharma additional Orphan Drug tag for LP-184
US FDA grants Lantern Pharma additional Orphan Drug tag for LP-184

By IPP Bureau - August 31, 2021

The drug is also intended for the treatment of glioblastoma multiforme

Sun Pharma to commercialise Winlevi in the US and Canada
Sun Pharma to commercialise Winlevi in the US and Canada

By IPP Bureau - August 31, 2021

Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago

Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis
Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis

By IPP Bureau - August 31, 2021

Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old

Dr. Reddy's announce launch two drugs in the US market
Dr. Reddy's announce launch two drugs in the US market

By IPP Bureau - August 31, 2021

Chlordiazepoxide Hydrochloride and Clidinium Bromide Capsules, USP are available in one strength of 5 mg/2.5 mg capsules in bottle count sizes of 100

Vivo Bio Tech enters long-term contract with Bio E
Vivo Bio Tech enters long-term contract with Bio E

By IPP Bureau - August 30, 2021

The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years

Union Minister Sonowal announces major plans for promoting Ayush in NE
Union Minister Sonowal announces major plans for promoting Ayush in NE

By IPP Bureau - August 30, 2021

A sum of Rs 70 crores and Rs 10 crores for a new Ayurvedic college in Assam and upgradation of the ayurvedic college in Guwahati respectively

Latest Stories

Interviews

Packaging